The therapeutic targeting of legumain has been proposed as a novel strategy in the treatment of AD, as legumain deficiency is shown to inhibit neuroinflammation and protect against Aβ-induced cognitive deficits and synaptic plasticity dysfunction [128]. Here, LGMN is linked to Alzheimer disease.